Podcasts about ADT

What is the role of PSA for early detection, and how does hormone therapy affect cancer patients? These are questions we dig into in this episode. https://bit.ly/4lC0ZUdIn This Episode:01:32 - Road Trip-South Carolina & Shout Halellujah Potato Salad02:38 - Fighting For Your Life Is Boring - Andrew Reynolds04:44 - Prostate Cancer - Risks and Treatment09:46 - Why Was Biden's Prostate Cancer Detected So Late?14:52 - Signs and Symptoms of Prostate Cancer16:08 - Gleason Scoring for Prostate Cancer Grade19:18 - Hormone Therapy - Androgen Deprivation33:27 - Prostate Cancer and Partners36:21 - OutroAbout 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Prostate cancer is the second-leading cause of cancer death in American men, behind lung cancer. Learn signs and symptoms, the role of PSA (prostate-specific antigen) for early detection and monitoring, how androgen-blocking therapy works, and how it affects patients and their partners.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

We were joined by people leaders from Glassdoor, Asana, and Upstart. We talked about the fragmented burnout and how it's hitting people differently, how performance expectations have shifted in the last 6-12 months, and more.---- Sponsor Links:

In this podcast episode, host Seamus introduces the SoSecure app by ADT, a free iOS emergency assistance application designed to connect users quickly with ADT agents who can contact emergency services on their behalf. Seamus offers a detailed walkthrough of the app's features, accessibility, and functionality, highlighting its usefulness—especially for those who rely on VoiceOver or have specific communication needs.Listeners are guided through the app's setup, key functions, and helpful tips to maximize its effectiveness and accessibility. Whether you are visually impaired, need a silent way to communicate during emergencies, or simply want a reliable safety app, this episode provides a thorough overview to get you started.SoSecure by ADT is a personal emergency response app that offers an emergency button with PIN cancellation, automated guardian text notifications, silent SOS chat, and location tracking groups. It is accessible to VoiceOver users and free to download on iOS devices, making it an essential tool for safety and peace of mind in situations where calling 911 directly isn't possible.Key Topics Covered:Introduction to ADT and SoSecure Seamus explains ADT's long history as a home security company and clarifies that the SoSecure app does not require an ADT home security system to be used.App Accessibility The app is about 95% accessible with VoiceOver, with a few minor limitations noted.Account Setup Users are required to create an account that includes providing an email, phone number, and a profile picture. A four-digit PIN must be created to cancel emergency calls.Emergency Button Functionality The app features a large emergency button that, when pressed, initiates a 10-second countdown during which the user can cancel the call by entering their PIN. If not canceled, an ADT agent contacts the user and, if necessary, emergency services.Automated Guardian Contacts Users can add up to five guardians (emergency contacts) who receive automated text alerts in an emergency, sent directly from ADT's system.SOS Chat Feature Text chat is available within the app to communicate with ADT agents silently, beneficial for those who are deaf, hard of hearing, or in situations where verbal communication is unsafe.Location Sharing and Groups The app includes a "My Groups" feature, similar to location tracking apps, allowing users to track and receive notifications about group members' locations, though this feature has limited accessibility.Settings Overview Seamus details the settings menu, including account editing, notification controls, PIN management (which requires a verification text), FAQ access, and legal/contact information.Demonstration of Adding and Removing Guardians The process of adding contacts from the user's phone and removing them is shown, with accessibility tips for blind users.Emergency Button Demonstration Seamus demonstrates using the emergency button and entering the PIN to cancel a test emergency call.Why Seamus Likes the App Seamus highlights the app's usefulness, especially when in unfamiliar locations or…

Jessica Zwaan joined us again to unpack the metrics that actually matter in HR today. We talked about the three buckets of metrics every People Leader should use, why the RANS test is a better way to measure engagement, and the one metric to rule them all (ELTV:CAC). ---- Sponsor Links:

Filipe Espósito faz uma visita ao ADT para contar como anda sua vida de criador de conteúdo, e qual é a cordo vestido do iOS.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

The Ramblin Gambler fields questions about working with independent casinos hosts, including how to boost your ADT score.

AUA2025: AUA Advanced Prostate Cancer Course CME Available: https://auau.auanet.org/node/43035 At the conclusion of this activity, participants will be able to: 1. Describe appropriate use of genetic testing (germline) and understand the importance of genetic counseling. 2. Describe appropriate use of somatic testing and treatments related to specific genetic alterations. 3. Identify appropriate combination therapy with ADT plus novel androgen access therapies and chemotherapy. Early treatment intensification including patient selection and adverse effects and benefits will be discussed in mHSCPC. 4. Explain the treatments for non-metastatic CRPC and oncologic outcomes, with recommendations based on AUA/SUO Guidelines. 5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on the latest AUA/SUO Guidelines. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Send us a textThis week we will be talking about Approved Document T. This episode content meets PC3 - Legal Framework & Processes of the Part 3 Criteria.Resources from today's episode:Websites:Law: https://assets.publishing.service.gov.uk/media/67167c02d100972c0f4c9b38/ADT_2024.pdfInformation:https://www.planningportal.co.uk/applications/building-control-applications/building-control/approved-documents/part-t-toilet-accommodation/approved-document-tThank you for listening! Please follow me on Instagram @part3withme for weekly content and updates or contact me via email me at part3withme@outlook.com or on LinkedIn. Website: www.part3withme.comJoin me next week for more Part3 With Me time.If you liked this episode please give it a rating to help reach more fellow Part3er's!Support the show

Frieda Möcker, Head of People & Culture at Sastrify, joined us on The Modern People Leader. We talked about the first steps she took to treat HR more like a product, how her team does sprint planning, and why she prefers “NCTs” over OKRs.---- Sponsor Links:

The Big Unlock Podcast · Reimagining Healthcare From Meaningful Use of Data to AI-Driven Equity – Podcast with Aneesh Chopra In this episode, Aneesh Chopra, Chief Strategy Officer at Arcadia shares a bold vision for advancing healthcare equity through smarter data use, AI, and workflow innovation. He unpacks the journey from the early days of “meaningful use” to today's AI-powered, value-based care landscape, highlighting how intelligent workflows can reach underserved populations and improve outcomes at scale. Aneesh introduces the concept of a “healthcare information fiduciary,” a model where apps and platforms act solely in the patient's best interest, free from institutional financial incentives. He discusses how this, combined with emerging AI capabilities and interoperability standards like CMS's FHIR APIs, can empower consumers and scale high-impact care delivery. With real-world success stories, from improved hospital ratings via conversational AI to national gains in ADT data coverage, this episode offers healthcare leaders a roadmap for driving innovation through public-private collaboration and patient-centered data strategy. Take a listen.

  What if your journey to becoming a physician didn't come with the burden of student debt, and instead, offered unique career opportunities and a profound sense of purpose? Join us as we chat with Army LTC Mary Alice Noel, MD, Navy CAPT Shauna F. O'Sullivan, DO, and Air Force Col Brian Neubauer, MD, to uncover the transformative power of the Health Professions Scholarship Program (HPSP). These esteemed guests share how the program not only covers full medical school tuition and provides a monthly stipend, but also opens doors to a diverse array of career paths in military medicine, offering a rewarding way to serve one's country.     Our discussion doesn't stop at financial benefits; it dives deep into the commitments and training opportunities that come with the HPSP. We unravel the journey through military medical training, from officer training schools to active duty for training (ADT) activities, and the unique advantages of being a Medical Corps officer during residency. You'll hear about the high match rates in military Graduate Medical Education (GME), the opportunities to pursue desired specialties, and the robust support systems that ensure both professional and personal growth.    The episode also highlights the rewarding nature of military deployments, beyond the traditional roles, with stories of humanitarian missions and crisis support. Learn about the vast opportunities available to military physicians, including roles in aviation and space, and the collaborative environments that enhance career development. Whether you're considering a future in military medicine or are just curious about the path less taken, this conversation is packed with insights and experiences that illustrate the immense fulfillment and camaraderie found in serving as a military physician. Chapters: (00:04) Health Professions Scholarship Program Overview (13:54) Military Medical Training and Benefits (24:30) Military GME and Residency Opportunities (36:54) Additional Training Opportunities (44:49) Military Medicine Career Opportunities (54:48) Military Medicine Deployments (01:04:15) Military Medicine Tribute and Resources   Chapter Summaries: (00:04) Health Professions Scholarship Program Overview   HPSP fully funds medical school for military physicians, offering financial benefits, unique training opportunities, and collaborative nature of military medicine.   (13:54) Military Medical Training and Benefits   HPSP journey includes officer training, ADT, service obligations, and benefits during residency for aspiring military medical officers.   (24:30) Military GME and Residency Opportunities   Military GME process for HPSP students includes a separate match, active duty tours, and high match rates for desired specialties.   (36:54) Additional Training Opportunities   Air Force physicians have various opportunities in residency, fellowships, and careers in clinical, academic, command, and integrated operations.   (44:49) Military Deployment and Career Opportunities   Nature's multifaceted military deployments offer diverse opportunities for training and career tracks, including GME and operational care for soldiers.   (54:48) Military Medicine Deployments   The HPSP offers financial freedom, unique deployment experiences, and leadership development in military medicine.   (01:04:15) Military Medicine Tribute and Resources   We thank all American service members and their families, highlighting their patriotism and invite listeners to explore the WarDocs podcast to find out more about the history and proud legacy of Military Medicine.     Take Home Messages: Financial Benefits of HPSP: The Health Professions Scholarship Program (HPSP) offers substantial financial advantages for aspiring military physicians, including full tuition coverage for medical school and a monthly stipend. This program offers the opportunity to graduate without the burden of student debt, making it an attractive option for those interested in pursuing a medical career within the military.   Diverse Training Opportunities: Military medicine offers unique training experiences, such as active duty for training (ADT) and clinical rotations at military hospitals across the country. These experiences, along with the opportunity to participate in both military and civilian residency programs, provide HPSP participants with a comprehensive and competitive medical education.   Career Pathways in Military Medicine: The military medical career offers a variety of pathways, including clinical, academic, command, and integrated operations roles. This flexibility allows physicians to explore different aspects of medicine and leadership within the Army, Navy, and Air Force.   Deployment and Humanitarian Roles: Military deployments offer rewarding experiences beyond traditional combat roles, including humanitarian assignments and support for civilian institutions during crises. These roles provide a sense of purpose and camaraderie, highlighting the impact military physicians can have on a global scale.   Comprehensive Support During Residency: Military Medical Corps officers benefit from competitive salaries, comprehensive insurance, and generous leave policies during residency. These benefits create a supportive environment that balances professional growth with personal life, ensuring the well-being of military physicians and their families.   Link for more information: Navy:  Navy HPSP: https://www.med.navy.mil/Accessions/Health-Professions-Scholarship-Program-HPSP-and-Financial-Assistance-Program-FAP/ Navy Medicine Recruiting - https://www.navy.com/careers-benefits/careers/medical/physician Navy Medical Corps - https://www.med.navy.mil/Medical-Corps/ Army: Army HPSP: https://www.goarmy.com/careers-and-jobs/specialty-careers/medical/amedd-scholarships Air Force: Air Force HPSP: https://www.airforcemedicine.af.mil/Organizations/Physician-Education-Branch/Medical-School-Scholarships/ Air Force Medical Corps: https://www.airforcemedicine.af.mil/About-Us/Medical-Branches/Medical-Corps/ Graduate Medical Education (GME): DHA GME Website: https://www.health.mil/Military-Health-Topics/DHA-GME Navy GME - https://www.med.navy.mil/Naval-Medical-Leader-and-Professional-Development-Command/Professional-Development/Graduate-Medical-Education/   Episode Keywords: Military Medicine, HPSP, Health Professions Scholarship Program, Medical Education, Army Medical Corps, Navy Medicine, Air Force Physicians, Medical Career, Military Hospitals, Military Match System, Graduate Medical Education, Medical Residency, Military Deployment, Humanitarian Assignments, Operational Roles, Military Scholarships, Medical Corps Officer, War Docs Podcast, Medical Training Opportunities   Hashtags: #MilitaryMedicine #HPSP #MedicalEducation #MilitaryCareer #ArmyNavyAirForce #HealthcareScholarship #MedicalTraining #WarDocsPodcast #MilitaryPhysicians #GraduateMedicalEducation     Honoring the Legacy and Preserving the History of Military Medicine The WarDocs Mission is to honor the legacy, preserve the oral history, and showcase career opportunities, unique expeditionary experiences, and achievements of Military Medicine. We foster patriotism and pride in Who we are, What we do, and, most importantly, How we serve Our Patients, the DoD, and Our Nation.   Find out more and join Team WarDocs at https://www.wardocspodcast.com/ Check our list of previous guest episodes at https://www.wardocspodcast.com/our-guests Subscribe and Like our Videos on our YouTube Channel: https://www.youtube.com/@wardocspodcast Listen to the “What We Are For” Episode 47. https://bit.ly/3r87Afm   WarDocs- The Military Medicine Podcast is a Non-Profit, Tax-exempt-501(c)(3) Veteran Run Organization run by volunteers. All donations are tax-deductible and go to honoring and preserving the history, experiences, successes, and lessons learned in Military Medicine. A tax receipt will be sent to you. WARDOCS documents the experiences, contributions, and innovations of all military medicine Services, ranks, and Corps who are affectionately called "Docs" as a sign of respect, trust, and confidence on and off the battlefield,demonstrating dedication to the medical care of fellow comrades in arms.     Follow Us on Social Media Twitter: @wardocspodcast Facebook: WarDocs Podcast Instagram: @wardocspodcast LinkedIn: WarDocs-The Military Medicine Podcast YouTube Channel: https://www.youtube.com/@wardocspodcast

ROH, MLW and GCW resultsBecome a supporter of this podcast: https://www.spreaker.com/podcast/nsc-wrestling-and-gaming-podcast--4855340/support.

Tiffany Stevenson (Former CPO, WeightWatchers), Jennifer Rettig (CPO, Pendo.io), and Kelli Dragovich (4x CHRO & Co-host of HR Heretics), joined us for MPL Live in San Francisco.We talked about the pressure HR leaders are under, what CEOs are really thinking, and how we can reimagine performance with simpler systems, clearer expectations, and more human conversations.---- Sponsor Links:

On this week's episode: Dice Coach Dials In Dice Sets Demons House Edge We also touch on sniping, 2-V mutant, ADT, negative progressions, black jack, stop loss and Ed teaches us some Greek. Call The Casino Tears Vent Line 229-NO SEVEN (667-3836) Now! Leave a message, ask a question or simply get something off your mind -  We might even play it on air!! NEW EPISODES DROP WEEKLY ON TUESDAYS - Please visit our home page at casinotears.com for more info, merch, and host contacts Extended versions will also drop Tuesdays on Patreon - Don't miss out :) Email: noseven@casinotears.com Patreon: https://www.patreon.com/CasinoTears Pro Shop: https://www.casinotears.vegas/shop/  Instagram: https://www.instagram.com/casinotearspodcast YouTube: https://www.youtube.com/@CasinoTears X: https://x.com/CasinoTears Reddit: https://www.reddit.com/r/casinotears  

Jessica Zwaan joined us again on The Modern People Leader to break down how to hire for a people ops as a product team.She shared the 5 core skillsets needed, the importance of t-shaped talent, and how to use case studies to spot product thinking in HR Candidates.---- Sponsor Links:

Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone

Alison and Amanda talk about the routine of renting clothes, curious encounters with customer support, savvy shopping strategies, and the days of dialing for time.  Sis & Tell, an award-winning weekly comedic podcast, is hosted by southern Jewish sisters the Emmy-nominated Alison Goldstein Lebovitz from PBS' The A List and Time Magazine's 2006 Person of the Year, Comedian Amanda Goldstein Marks.

Matt McFarlane and Haris Ikram joined us for a live session to break down everything modern HR leaders need to know about compensation—from philosophy and strategy to pay transparency and AI tools. Together, they shared a forward-thinking playbook for tackling merit cycles, aligning job architecture, and driving better employee experiences through data and design.---- Sponsor Links:

My guest this week is DeLu Jackson, Executive Vice President and Chief Marketing and Communications Officer at ADT. A seasoned executive with over 20 years of experience, DeLu has led marketing transformation at some of the world's most iconic brands, including McDonald's, Audi, Kellogg's, Nissan, Subaru, ConAgra, and now ADT. He's known for his data-driven, customer-first approach and for helping redefine what protection and connection mean in the smart home and small business security space. With an undergraduate degree in Politics from Princeton University and an MBA from NYU Stern School of Business, he brings both intellectual rigor and real-world results to the table. He's also an independent board director and a recognized thought leader in marketing, growth, and digital innovation. 

My guest today is Nigel Jones who is making his third appearance on the Tribe Sober podcast – our conversations always get plenty of downloads and Nigel is a mine of valuable information! In this episode:- Nigel's secret to success was becoming a non-drinker from Day One — rather than a drinker trying to quit. He used the metaphor of a mountain — put yourself on top from the start rather than struggling to climb it. It's our beliefs and values shape our identity, then it's our identity that drives our intentions and actions. We need to flip our beliefs: once we truly believe that alcohol is a poison, then everything changes. Nigel is a qualified Hypnotherapist and he came up with a great analogy to explain how hypnotherapy works Our conscious mind is often resistant and has “bouncers” to prevent new information from entering our subconscious Hypnotherapy can remove those bouncers allowing better access to the subconscious Drinking creates a program in our subconscious and hypnotherapy helps us to replace it with healthier programs. Nigel is also qualified in NLP - Neuro Linguistic Programming which can help us to rewire our beliefs We both agreed that Drinking is deeply tribal — Nigel calls the Alcohol Drinking Tribe the ADT People protect their ADT which is why we often encounter resistance when we announce that we have quit drinking When we leave the ADT, we need to find another tribe quickly so that we don't feel isolated or judged In fact Connection is the opposite of addiction and That's why we set up Tribe Sober which offers connection, vulnerability, and authenticity  – so if you're ready to swop your drinking tribe for Tribe Sober then click here to check out our membership program Nigel shares his own inspiring story called Walking Back to Happiness He's also a certified hypnotherapist, NLP practitioner and life coach. He offers 1:1 and group coaching, for habit change, phobias, and anxiety. His website and social media is 9kmby9am.com  Nigel's previous podcast interviews with Tribe Sober are here and here   Episode Sponsor This episode is sponsored by the Tribe Sober Membership Program.  If you want to change your relationship with alcohol then sign up today - here is the link.  Help us to spread the word! We made this podcast so that we can reach more people who need our help.  Please subscribe and share. We release a podcast episode every Saturday morning. You can follow Tribe Sober on Facebook, Twitter and Instagram.  You can join our private Facebook group HERE PS: How to Leave a Rating/Review in Apple Podcasts (on an iOS Device) Open the Podcasts app. EASY. Choose “Search” from the bottom row of icons and enter the name of the show (e.g. Recover Like a Mother) into the search field. Select the show under Shows (not under Episodes). Scroll down past the first few episodes until you see Ratings & Reviews. Click Write a Review underneath the displayed reviews from other listeners. You'll then have the option to rate the show on a 5-star scale and write a review (you can rate without writing too but it's always good to read your experience).  

Abby Brennan joined us on The Modern People Leader. We discussed the power of ONA as the “shadow org chart,” how it reveals hidden influencers, and why it may be key to building smarter, more connected teams in the age of AI.---- Sponsor Links:

You should know this: The common approach to prostate cancer is NOT the best path for your long-term health. In this episode, Dr. Stephen Petteruti uncovers essential truths behind President Joe Biden's prostate cancer diagnosis. Dr. Stephen critically examines conventional treatments, such as androgen deprivation therapy (ADT), highlighting their severe side effects. He also challenges the long-held medical belief linking testosterone to cancer progression, presenting innovative and less harmful alternative treatments.Discover safer, science-backed alternatives your doctor might not mention. It's time to take control of your health with knowledge, clarity, and confidence.Don't miss this episode: Biden's Prostate Cancer: The TRUTH Doctors Don't Want You To Know!Enjoy the podcast? Subscribe and leave a 5-star review!Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com  YouTube: https://www.youtube.com/@dr.stephenpetteruti LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/dr.stephenpetteruti Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.#CastrationCrisis #ProstateCancer #ProstateChoices

AUA2025: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025 CME Available: https://auau.auanet.org/node/42997 At the conclusion of this activity, participants will be able to: 1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral antiandrogens. Furthermore, to recognize high-volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team. 2. Non-Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): The learner will be skilled to diagnose M0 CRPC and be able to educate patients about using either enzalutamide or apalutamide or darolutamide added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three oral agents and to educate patients about side-effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease Non-metastatic Castrate-Resistant Prostate Cancer (M0 CRPC): Diagnose M0 CRPC and be able to educate patients about using novel oral antiandrogens added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these novel oral agents and to educate patients about side effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease state. 3. Metastatic Castrate-Resistant Prostate Cancer (M1 CRPC): Describe and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and be able to educate their patients on treatment options and participate in a multidisciplinary team caring for men with this disease state of far-advanced prostate cancer. 4. Describe that advanced prostate cancer is a complex group of disease states with an ever-changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients. 5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents, and novel AR targeted agents emerging in 2025 and beyond.

On this episode of the podcast, cancer researcher, physician, and author Dr. Steven Quay dives into President Joe Biden's recent cancer disclosure and sheds light on his broader medical history — including brain aneurysms, pulmonary embolisms, and past cancers. Dr. Quay breaks down the slow progression of prostate cancer, raising questions about the timing and transparency of Biden's newly revealed diagnosis. He also highlights the importance of PSA screenings after age 50 and explores the risks and benefits of androgen deprivation therapy (ADT).Furthermore, Dr. Quay discusses his forthcoming book, “The Code as Witness: The COVID Genome Reveals Its Lab Origins and How to Prevent Future Outbreaks,” where he makes the case for COVID's lab-based origins and calls for a federal ban on gain-of-function research to prevent future pandemics.Follow Dr. Steven Quay on X by searching for his handle: @Quay_Dr and learn more at www.DrQuay.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jessica Zwaan joined us again on The Modern People Leader to unpack how to structure a people ops as a product team. She shared four ways to build an HR squad, how to use a spider diagram for squad design, and why it's smart to pilot just one squad first.---- Sponsor Links:

这是一个独属于女性的夜晚。4月27日，耐克全球女子夜跑系列赛After Dark Tour来到上海，3500名女性跑者在南京东路集结，将上海的夜「跑为己有」。10公里结束，她们在跑百巷再次聚首，聊聊这段旅程中的汗水、成长与感动。本期节目，运动博主孙佳祺、赵依侬客串我们的代班主播，和跑龄两个月的「老跑者」颜如晶、在训练过程里能同时拥有天使和魔鬼两幅面孔的小彩教练，以及20位参赛跑者一起「续摊儿」，不仅回味了一番After DarkTour强烈的后劲，还有轻松的跑步趣事和坚韧的女性内核：当我们穿上跑鞋，不只是踏上赛道，更是在一步步中靠近那个更坚定、更自由的自己。- 聊天的人 -代班主播：孙佳祺、赵依侬嘉宾：颜如晶，耐克女子夜跑参赛者小彩，耐克NRC 城市教练ADT参赛者和跑者- 时间轴 -01:47 After Dark Tour之后，跑百巷迎来一场「全女局」05:19 颜如晶：为了准备这场10K，我先去跑了个半马10:14 从「厌跑」到半马，是怎么一步步跑起来的18:43 参加ADT的跑者们，发枪前后的反差也太大了28:26 全女赛事的特别之处？垃圾很少，还香香的32:45 在舞台一样的赛道上跑步，是种什么体验？36:32 这是属于我的勋章，不需要任何人帮忙戴上37:43 在这个夜晚，女性之间的温暖连结悄然发生39:27 夜跑的「危险」主要体现在...夜宵的诱惑？49:00 夜幕降临，正是探索城市新样貌的好时机53:36 虽然都说不忘初心，但过程有时更有意义01:01:15 不用比较，跑步是一项完全由你自己掌控的运动01:04:37 出来跑步，最重要的是先「出来」01:06:43 泡泡跑、动物园跑、胶片跑，怎么有趣怎么跑！01:09:42 跑步没那么难，但科学训练才是跑得久的秘诀01:12:17 当我们穿上跑鞋、走上赛道，成为真正的自己- 本节目由耐克出品，JustPod制作发行 -- 制作团队 -策划：孙佳祺、赵依侬、Jimmy、Tiara、王童语统筹：Cora、王冰倩制作：王童语声音设计：陆佳杰、马若晨节目运营：邓逸轩

Bryan Power, Head of People at Nextdoor, joined us on The Modern People Leader. We talked about how the company is navigating its “third era” under the return of co-founder Nirav Tolia. We explored “The Founders Mentality”, embracing an owner's mindset, and Nextdoor's AI bootcamp.---- Sponsor Links:

Today on the Dr. Geo Prostate Podcast, we're joined by world-renowned oncologist Dr. Rana McKay of UC San Diego Health. With training from Harvard and Dana-Farber, Dr. McKay breaks down the evolving landscape of triplet therapy—a combination of ADT, an ARPI (androgen receptor pathway inhibitor), and chemotherapy (docetaxel)—and how it's changing survival outcomes for men with advanced prostate cancer.In this enlightening and practical episode, Dr. Geo and Dr. McKay discuss:What triplet therapy is and how it compares to doublet therapyThe latest clinical trials and the importance of timing treatmentHow to personalize care for high- and low-volume metastatic prostate cancerWhen to escalate treatment—and when quality of life may outweigh aggressive therapyThe role of genomic tools like the Decipher score in decision-makingSide effect profiles, cold therapy, fasting, and integrative strategiesWhy communication and patient values should drive treatment decisionsIf you or a loved one is facing a diagnosis of advanced prostate cancer, this episode offers invaluable clarity and hope.

Jessica Zwaan, COO at Talentful and author of Built for People,  joined us on The Modern People Leader.We talked about “human ops” versus “people ops”, the sprint planning process for her people team, and how nobody gets people ops as a product 100% right (and that's ok).---- Sponsor Links:

Send us a textAward-winning excellence doesn't happen by accident. After receiving the news that Habitation Investigation had earned the prestigious "Best in the Midwest" award for the third consecutive year, we decided to peel back the curtain and share what makes our home inspection company different from the competition.This episode explores the factors that contribute to our continued success, from our customer-first approach to our ethical business practices. With over 1,700 Google reviews and a stellar 4.9-star rating, we've built a reputation on clear communication, thorough inspections, and reports that set the standard for the industry. Our team shares how we've grown from our humble beginnings in 2002 to become one of Ohio's premier inspection companies, expanding our services based directly on client requests rather than arbitrary business decisions.We tackle a particularly important topic for homeowners: privacy protection. Unlike many inspection companies that generate revenue by selling client information to third parties, we maintain strict privacy standards. Our single partnership with ADT is completely optional for clients and directs benefits to charities rather than our bottom line. We also discuss the value of maintenance inspections every 3-5 years and regular radon testing—services that can save homeowners thousands by catching small issues before they become expensive problems.What truly sets an inspection company apart isn't fancy technology or marketing gimmicks—it's having inspectors who genuinely care about their clients and communicate clearly without fear-mongering. Whether you're a homeowner, real estate professional, or aspiring entrepreneur, this episode offers valuable insights into building a service business based on integrity, customer care, and consistent quality. Ready to learn what makes a home inspection company worthy of multiple industry awards? Listen now and discover how excellence becomes a habit.Support the showTo learn more about Habitation Investigation, the Three-time Winner of the Best Home Inspection Company in the Midwest Plus the Winner of Consumer Choice Award for Columbus Ohio visit Home Inspection Columbus Ohio - Habitation Investigation (homeinspectionsinohio.com) NBC4 news segments: The importance of home inspections, and what to look for | NBC4 WCMH-TV Advice from experts: Don't skip the home inspection | NBC4 WCMH-TV OSU student's mysterious symptoms end up tied to apartment's air quality | NBC4 WCMH-TV How to save money by winterizing your home | NBC4 WCMH-TV Continuing Education for Ohio Agents Scheduled classes Continuing Education for Ohio Agents Course lis...

Reggie Marable is the Head of Global Sales at Sierra, a conversational AI platform for businesses. Sierra enables companies like ADT, Sonos, SiriusXM, and WeightWatchers to build AI agents that transform customer experiences. The company has rapidly become a hypergrowth leader in Silicon Valley, recently securing a funding round that values it at $4.5 billion. Before joining Sierra, Reggie was the Head of Sales in North America at Slack and the Area Vice President of Enterprise Sales at Salesforce.  In Today's Episode We Discuss:  02:50 “What I Learned from Failing Early as a CRO” 06:06 The Most Effective Sales Strategy and the BS Sales Methodology 06:55 How to Build Sales Processes from Scratch 12:28 When and How to do Verticalised Sales Teams 14:15 How to Become World Class as Sales Prospecting and Outbound 17:21 How to Use Proof of Concepts to Win Enterprise Deals 22:04 Enterprise vs. Self-Serve: Both or One and How 30:09 Building a Sales Team from Scratch 37:39 Structuring the Hiring Process 41:14 How Founders F*** Up Hiring in Sales 46:25 Handling Salary and Title Expectations 51:36 How to Run Effective Deal Cycles 57:06:07 How to do Onboarding for New Sales Hires 59:07:48 How to do Post Mortems in Sales Processes 01:04:24 Negotiating Enterprise Deals 01:08:04 Quick Fire Round: Sales Tactics and Strategies  

Taylor Bradley, VP of Talent Strategy and Success at Turing, joined us on The Modern People Leader.We talked about why every HR team needs to create an AI “prompt pantry”, how Turing “AI'd” their way out of onboarding 800 employees in five days, and how to build AI workflows for HR.---- Sponsor Links:

On this week's show: Yale has a new lock with easy integration with ADT systems, Google kills 1st and 2nd gen Nest devices, Aqara releases a few new products, Wiz shows off a new HDMI TV light, light bulb cameras are a thing, Roku has new cameras, Eve joins Home Assistant, letters from the mailbag, a pick of the week, project updates, and so much more!

Dr. Rohan Garje shares the updated recommendations for the ASCO guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer. He discusses the systemic therapy options for patients based on prior therapy received in the castration-sensitive and non-metastatic castration-resistant settings. He emphasizes personalizing treatment choices for each individual, considering patient-specific symptoms and signs, treatment-related toxicities, potential drug interactions, cost, and access. He also reviews recommendations on response assessment. The conversation wraps up with a discussion of potential future updates to this guideline, as the guideline transitions into a “living guideline” on mCRPC. Read the full guideline update, “Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update”. Transcript This guideline, clinical tools, and resources are available at www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology.      Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Rohan Garje from Miami Cancer Institute Baptist Health South Florida, lead author on, “Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.” Thank you for being here today, Dr. Garje. Dr. Rohan Garje: Absolutely. Thank you so much for having me, Brittany. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Garje, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to start on the content of this guideline, first, could you provide us an overview of the purpose of this guideline update? Dr. Rohan Garje: Sure. So ASCO has guidelines for prostate cancer and the specific guideline which we have updated for metastatic castrate-resistant prostate cancer was originally published in 2014. It's almost a decade. It's been a long time due for an update. Over the last decade, we have seen a lot of advances in the treatment of prostate cancer, specifically with regards to genomic testing, newer imaging modalities, and also the treatment landscape. Now we have newer options based on genomic targets such as PARP inhibitors, we have radiopharmaceuticals, a newer variant of chemotherapy, and also some specific indications for immunotherapy which were not addressed previously. Because all these advances have been new, it was really important for us to make an update. In 2022, we did make a rapid update with lutetium-177, but these additional changes which we have seen made it an appropriate time frame for us to proceed with a newer guideline. Brittany Harvey: Absolutely. It's great to hear about all these advances in the field to provide new options. So I'd like to next review the key recommendations from this guideline. So let's start with the overarching principles of practice that the panel outlined. What are these key principles? Dr. Rohan Garje: As a group, all the panel members came up with some ground rules: What are necessary for all our patients who are being treated for metastatic CRPC? First, the founding aspect was a definition for what is metastatic CRPC. So we defined metastatic CRPC as castrate level of testosterone with evidence of either new or progressive metastatic disease on radiological assessments or patients who have two consecutive rising PSAs in the setting of existing metastatic disease. We also emphasized on the need for germline and somatic testing for patients with metastatic prostate cancer at an earliest available opportunity because it is critical to select appropriate treatment and also right treatment for patients at the right time. And we actually have a concurrent guideline which addresses what genes to be tested and the timing. The other principles are patients should continue to receive androgen deprivation therapy or undergo surgical castration to maintain castrate level of testosterone. Now the key aspect with these guidelines is personalizing treatment choices. As you can see the evolution of treatment options for prostate cancer, the drugs that were initially developed and approved for prostate cancer were primarily in castrate-resistant settings, but now most of these drugs are being utilized in castrate-sensitive. So, when these patients develop castration resistance, the challenges are there are no appropriate particular drug-specific guidelines they meet. So, it's very important for the clinicians to be aware of what treatments have been received so far prior to castration resistance so that they can tailor the treatment to patient specific situations. In addition, prior to choosing a therapy, it is important for the physicians to consider patient specific symptoms or signs, treatment-related toxicities, potential drug interactions, cost, and also access to the drugs. There may be multiple treatment options available for the patients, but for a patient specific scenario, there may be a drug that may be more promising than the others. So, it is important to tailor the drug choices based on patients' unique circumstances. The panel also recommends to early integrate palliative and supportive care teams for symptom management and also discuss goals of care with the patient as each patient may have unique needs and it's important for physicians to address those concerns upfront in the care. The panel also suggests patients to receive RANK ligand inhibitors such as denosumab or bisphosphonates such as zoledronic acid to maintain the bone strength to prevent skeletal-related events. Finally, I would like to also emphasize this point about the lack of randomized clinical trial data for optimal sequencing of therapies for patients with metastatic CRPC. As I previously alluded, we have taken into account all ongoing clinical trials, prior published data, and came up with a format of preferred drugs based on prior treatments and, I think, by following these several clinical principles which I just mentioned, we can optimally choose and utilize best treatments for patients with metastatic CRPC. Brittany Harvey: Absolutely. These principles that you just outlined are important for optimal patient care, and then I want to touch on one of those things. You talked importantly about the treatments received so far. So in the next set of recommendations, the role of systemic therapy was stratified by the prior therapy received in the castration-sensitive and non-metastatic castration-resistant setting. So starting with what does the panel recommend for patients who are previously treated with androgen deprivation therapy alone in these previous settings and whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Rohan Garje: There are multiple treatment options based on prior treatment received. So for patients who received only ADT for their castration-sensitive disease, the panel strongly urges to get HRR testing to check for homologous recombinant repair related changes, specifically for BRCA1 and BRCA2 mutations, because we have three studies which have really shown significant clinical benefit for patients who have BRCA1 and BRCA2 mutations with drugs such as the combination of talazoparib and enzalutamide or olaparib with abiraterone or niraparib with abiraterone. Unless we test for those mutations, we'll not be able to give these agents upfront for the patients. In the HRR testing, if patients have HRR alterations but they are in genes which are non-BRCA, the guideline panel recommends to utilize talazoparib and enzalutamide based combination therapies. Now, if they don't have HRR alterations then there are multiple treatment choices available. It could either include androgen receptor pathway inhibitors such as abiraterone with prednisone. We could also consider docetaxel chemotherapy. The alternate choices for androgen receptor pathways include enzalutamide or the newer agents such as apalutamide and docetaxel. So, as you can see there are multiple options available, but the panel definitely emphasizes to test for HRR testing because this gives patients access to more precision therapies at this point. There may be various scenarios where a unique drug may be available for a specific patient situation. For example, patients who have very limited disease burden and may have one or two metastatic lesions, after a multidisciplinary discussion, targeted local therapies such as radiation or potentially surgery could also be offered. In select patients who have very indolent disease where they are castrate-resistant based on slow rising PSA, low-volume disease or asymptomatic disease can consider sipuleucel-T. And in patients who have bone-only metastatic disease, we could also consider radium-223, which is primarily now utilized for patients who have symptomatic bone disease. Brittany Harvey: Great. I appreciate you reviewing all those options and talking about how important it is to tailor treatment to the individual patient. So then the next category of patients, what is recommended for those who have been previously treated with ADT and an androgen receptor pathway inhibitor and whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Rohan Garje: So for patients who received ADT along with an androgen receptor pathway inhibitor, which we consider would be a most common cohort because most patients now in castration-sensitive setting are receiving androgen receptor pathway inhibitor. It was different in the past where five or six years back ADT alone was the most common treatment, but fortunately, with enough awareness and education, treatment choices have improved. Patients are now receiving ADT and ARPI as the most common choice of drug. Once again, at this point the panel emphasizes to consider HRR testing in there is enough data for us to suggest that patients who have alterations in the HRR pathway definitely will benefit with the PARP inhibitor. You know the multiple options, but specifically we speak about olaparib. And then if they are HRR-negative, we prefer patients receive agents such as docetaxel or if they are intolerant to docetaxel, consider cabazitaxel chemotherapy, options such as radium-223, and if they have a specific scenario such as MSI-high or mismatch repair deficiency, pembrolizumab could also be considered. The panel also discussed about the role of a second ARPI agent. For example, if patients progressed on one androgen receptor pathway inhibitor, the second androgen receptor pathway inhibitor may not be effective and the panel suggests to utilize alternate options before considering androgen receptor pathway inhibitor. There may be specific scenarios where a second ARPI may be meaningful, specifically, if alternate choices are not feasible for the concern of side effects or toxicities or lack of access, then a potential ARPI could be considered after progression on ARPI, but the panel definitely encourages to utilize alternate options first. Brittany Harvey: Great. Thank you for outlining those options as well for those patients. So then the next category, what is recommended for patients who have been previously treated with ADT and docetaxel? Dr. Rohan Garje: For patients who received ADT and docetaxel and were never treated with androgen receptor pathway inhibitors, the panel again emphasizes on HRR testing. If they have BRCA1 and 2 mutations, the combination therapies of talazoparib with enzalutamide, olaparib with abiraterone, or niraparib with abiraterone are all good choices. If they don't have BRCA mutations but they have other HRR mutations, the panel suggests to potentially utilize talazoparib with enzalutamide. And if they do not have any HRR alterations, the options could include androgen receptor pathway inhibitors such as abiraterone or enzalutamide. I want to emphasize that these are preferred options, but not the only options. As you can see, there are multiple options available for a particular clinical situation - so the ability of the physicians to access particular combinations, the familiarity of those drugs or the patient's unique situation where they have other medications which can potentially interact with a choice of agents. So I think based on access, based on cost and patients' concurrent illness with potential drug interactions can make one particular combination of therapy better over the other options. Brittany Harvey: Absolutely. That's key to keep in mind that access, contraindications, and cost all play a role here. So then the next set of recommendations. What are the key recommendations for patients who have previously been treated with ADT, an androgen receptor pathway inhibitor, and docetaxel who now have mCRPC? Dr. Rohan Garje: Yes. In this group, the options remain, again, broad. We utilize PSMA imaging here specifically and if they are positive on PSMA imaging, lutetium-177 is a good option. If they do not have PSMA-positive disease on PSMA imaging but if they have HRR alterations, olaparib could be utilized. And if they are negative on PSA imaging, they don't have HRR alterations, then alternate options could include cabazitaxel, radium-223. And if they have MSI-high or deficiency in mismatch repair, pembrolizumab could be utilized in this setting. Brittany Harvey: Thank you for outlining those options as well. So then next the panel addressed treatment options for de novo or treatment emergent small cell neuroendocrine carcinoma of the prostate. What are those key recommendations? Dr. Rohan Garje: Yes. This is a very high unmet need group because there are limited clinical trials, especially prospective clinical trials addressing treatment options for this group. Most of our current guidelines are always an extrapolation from lung small cell cancer based guidelines, but the panel recommends to utilize cisplatin or carboplatin along with etoposide as a preferred choice for this group. Also, an alternate option of carboplatin along with cabazitaxel could be considered for this cohort. The panel also encourages participation in clinical trials. There are numerous trials ongoing now in smaller phase studies and I think it's important for patients to consider these trials as well, because this will give them access to newer agents with potential biological targets. In addition to these agents in specific scenarios or potentially case by case basis, because we don't have prospective data, so we have made it as a select case by case basis to consider adding immunotherapy along with platinum-based chemotherapy followed by maintenance immunotherapy, which is currently a standard of care in small cell lung cancer. But the data is so limited in prostate cancer, so the panel suggested that it has to be a case by case basis only. The alternate options also include lurbinectedin, topotecan, tarlatamab upon progression on platinum-based chemotherapy. Brittany Harvey: Yes. It's important to have these recommendations in these unique situations where there is really a lack of data. So then the final set of recommendations I'd like to cover, what does the panel recommend for how clinicians should assess for response while patients are on systemic therapy and what scans are recommended for this response assessment? Dr. Rohan Garje: Yes. Again, this is another strong emphasis of the panel for global assessment of the patients. Traditionally, patients and physicians per se are heavily reliant on PSA as an accurate marker for response. This is in fact true in earlier phases of prostate cancer either in castrate-sensitive setting or localized prostate cancer setting. But as patients evolve into castrate-resistant, we don't want to heavily rely on PSA alone as a marker of response. The panel suggests to incorporate clinical response, radiological response, and also include PSA as a component, but not just rely primarily on PSA. So the panel also suggests that patients should get a bone scan and a CT scan every three to six months while on treatment to assess for appropriate response or for progression. And now one key important aspect, we are all aware about the evolving role of PSMA-based imaging with several of these new agents that are currently available. We do acknowledge these scans definitely have an important role in the care for patients with metastatic prostate cancer. Currently, the utility is primarily to select patients for lutetium-based therapy and also in situations where the traditional scans such as technitium 99 bone scan or CT scan are equivocal, then a PSMA-based imaging can be helpful. Now we are also aware that there are newer studies coming up, prospective data coming up for the role of PSMA-based imaging for response assessment. We are hoping to update the guidelines if we get access to newer data, but currently we have not recommended the utility of PSMA-based imaging for response assessments. Brittany Harvey: Understood. And I appreciate you describing where there is data here and where there's a lack of data to currently recommend. And we'll look forward to future updates of this guideline. Coming back to – at the start you mentioned how much has changed since the last guideline update. So Dr. Garje, in your view, what is the importance of this update and how will it impact both clinicians and patients with metastatic castration-resistant prostate cancer? Dr. Rohan Garje: The updated guidelines are designed to have a significant impact on clinical practice and also patient outcomes by providing clinicians with a comprehensive evidence-based framework for managing patients with metastatic CRPC. And also, by using these guidelines can make informed decisions, can select therapies tailored to patients' unique genomic status, clinical situation, where they are in the course of the cancer based on what they received previously. Also utilizing these guidelines, we can potentially improve patient outcomes, improve survival, and importantly have efficient use of healthcare resources. Brittany Harvey: Absolutely. We're always looking for ways to improve patient outcomes and survival. I want to wrap us up by talking a little bit about the outstanding questions in this field. So earlier you had mentioned about prospective data to come about PSMA PET scans, but what other outstanding questions are there for patients with metastatic castration-resistant prostate cancer? And what evidence is the panel looking forward to for future updates? Dr. Rohan Garje: We do have now rapidly evolving data specifically about the utility of the radiopharmaceutical lutetium-177 prior to chemotherapy. We are hoping that with newer data we can make some changes to the guideline based on that. We are also looking at newer drugs that are coming up in the pipeline, for example, androgen receptor degraders. We are looking at data that might potentially help based on bispecific T-cell engagers and newer radiopharmaceuticals. So I think in the next few years, we will definitely update all the guidelines again. But this time we are trying to do it more proactively. We are following a newer model. We are calling it as ‘living guidelines' where we are actually utilizing week by week updates where we look at the literature and see if there is any potential practice impacting change or publication that comes up. And we are trying to incorporate those changes as soon as they are available. That way patients and practicing physicians can get the latest information available through the guidelines as well. Brittany Harvey: That's great to hear. Yes, we'll await this data that you mentioned to continuously update this guideline and continue to improve patient outcomes for the future. So Dr. Garje, I want to thank you so much for your time to update this guideline. It was certainly a large amount of recommendations, and thank you for your time today, too. Dr. Rohan Garje: Thank you so much for having me here. And it's always nice talking to you. Brittany Harvey: And finally, thank you to our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Live from AUA2025: Advances in ADT Program CME Available: https://auau.auanet.org/content/LiveFromAUA2025#group-tabs-node-course-default1 At the conclusion of this CME activity, participants will be able to: 1. Employ the latest AUA and NCCN guidelines (Version 1.2025) related to Androgen Deprivation Therapy (ADT) into practice 2. Evaluate clinical outcomes, efficacy, and safety profiles of different types of ADT including oral and parenteral LHRH agonists and GnRH receptor antagonists in different treatment settings. 3. Compare testosterone recovery, treatment efficacy, safety profiles, and patient preferences between different modalities of ADT. 4. Recognize common side effects associated with different types of ADT and its combination therapies as well as strategies to mitigate these adverse effects to improve patient outcomes. 5. Implement a multi-disciplinary approach in managing advanced prostate cancer with ADT. 6. Evaluate the future directions and ongoing research that may impact the use of ADT in clinical practice.

Check out this week's QuadCast as we highlight the predictive abilities of AI for ADT duration in prostate cancer, how consolidative chemoRT benefits patients with unresectable gallbladder cancer, the benefits of immunotherapy in clear cell GYN cancer, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Molly Sands, Head of the Teamwork Lab at Atlassian, joined us on The Modern People Leader.We talked about Atlassian's latest research on the three things the best teams do differently, the power of unleashing collective knowledge, and why distributed teams have a headstart on AI adoption.---- 

Marine Corps Veteran Edgar Rodriguez joins Joe on this episode of Veteran On the Move. Edgar shares his journey transitioning into the communication industry, highlighting his experience in sales with ADT and the valuable lessons learned through Wolf Management's Capstone program. They discuss the power of connecting with like-minded individuals, building strong relationships, and the role of executive coaching in establishing a solid team based on the five pillars of business. Ultimately, Edgar emphasizes the significance of discovering one's passion and forging a fulfilling path. Episode Resources:  Master the Network Edgar's LinkedIn   About Our Sponsors Navy Federal Credit Union   Navy Federal Credit Union has made it their mission to help people in the military community. Navy Federal Credit Union is open to all branches of the military, Veterans and their families. They have lots of flexible savings and investing options to help their members reach their financial goals. Don't miss out. The sooner you start building your finances with savings and investing options, the better off they could be in the long run.  At Navy Federal, our members are the mission.        Join the conversation on Facebook! Check out Veteran on the Move on Facebook to connect with our guests and other listeners. A place where you can network with other like-minded veterans who are transitioning to entrepreneurship and get updates on people, programs and resources to help you in YOUR transition to entrepreneurship.   Want to be our next guest? Send us an email at interview@veteranonthemove.com.  Did you love this episode? Leave us a 5-star rating and review!  Download Joe Crane's Top 7 Paths to Freedom or get it on your mobile device. Text VETERAN to 38470. Veteran On the Move podcast has published 500 episodes. Our listeners have the opportunity to hear in-depth interviews conducted by host Joe Crane. The podcast features people, programs, and resources to assist veterans in their transition to entrepreneurship.  As a result, Veteran On the Move has over 7,000,000 verified downloads through Stitcher Radio, SoundCloud, iTunes and RSS Feed Syndication making it one of the most popular Military Entrepreneur Shows on the Internet Today.

Pat Wadors, CHRO at Intuitive, joined us on The Modern People Leader. We talked about how to find and amplify the golden nuggets of your culture, the three layers of a great employee experience, why you need to “touch the elephant”, and what kids' stories can teach us about leadership.---- 

In this episode of the Dr. Geo Prostate Podcast, we welcome Dr. Jonathan Lischalk, Director of Genitourinary Cancers at MedStar Georgetown University Hospital and former Medical Director at NYU's NYCyberKnife Center. Dr. Lischalk breaks down the evolution of radiation oncology and how cutting-edge imaging and targeted SBRT (Stereotactic Body Radiation Therapy) are reshaping prostate cancer treatment.We explore how imaging advances like MRI and PSMA PET scans are enabling unprecedented precision, the future of genetic-based personalization in prostate cancer therapy, and why fewer, more focused radiation sessions might soon become the new standard. From understanding the biology of radiation dosing to upcoming trials eliminating ADT in select patients, this is a must-listen for anyone looking to stay informed on the forefront of cancer care.

JCO PO author Dr. Timothy Showalter at Artera and University of Virginia shares insights into his JCO PO article, “Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer” . Host Dr. Rafeh Naqash and Dr. Showalter discuss how multimodal AI as a prognostic marker in nonmetastatic castration-resistant prostate cancer may serve as a predictive biomarker with high-risk patients deriving the greatest benefit from treatment with apalutamide. TRANSCRIPT  Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations where we'll bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast Editor for JCO Precision Oncology and assistant professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are excited to be joined by Dr. Timothy Showalter, Chief Medical Officer at Artera and professor of Radiation Oncology at the University of Virginia and author of the JCO Precision Oncology article entitled, “Digital Pathology Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase 3 Trial in Men with Non-Metastatic Castration Resistant Prostate Cancer.” At the time of this recording, our guest's disclosures will be linked in the transcript. Dr. Showalter, it's a pleasure to have you here today. Dr. Timothy Showalter: It's a pleasure to be here. Thanks for having me. Dr. Rafeh Naqash: I think this is going to be a very interesting discussion, not just from a biomarker perspective, but also in terms of how technologies have evolved and how we are trying to stratify patients, trying to escalate or deescalate treatments based on biomarkers. And this article is a good example of that. One of the things I do want to highlight as part of this article is that Dr. Felix Feng is the first author for this article. Unfortunately, Dr. Felix Feng passed away in December of 2024. He was a luminary in this field of prostate cancer research. He was also the Chair of the NRG GU Committee as well as Board of Directors for RTOG Foundation and has mentored a lot of individuals from what I have heard. I didn't know Dr. Feng but heard a lot about him from my GU colleagues. It's a huge loss for the community, but it was an interesting surprise for me when I saw his name on this article as I was reviewing it. Could you briefly talk about Dr. Feng for a minute and how you knew him and how he's been an asset to the field? Dr. Timothy Showalter: Yeah. I'm always happy to talk about Felix whenever there's an opportunity. You know, I was fortunate to know Felix Feng for about 20 years as we met during our residency programs through a career development workshop that we both attended and stayed close ever since. And you know, he's someone who made an impact on hundreds of lives of cancer researchers and other radiation oncologists and physicians in addition to the cancer patients he helped, either through direct clinical care or through his innovation. For this project in particular, I first became involved soon after Felix had co-founded Artera, which is, you know the company that developed this. And because Felix was such a prolific researcher, he was actually involved in this and this research project from all different angles, both from the multimodal digital pathology tool to the trial itself and being part of moving the field forward in that way. It's really great to be able to sort of celebrate a great example of Felix's legacy, which is team science, and really moving the field forward in terms of translational projects based on clinical trials. So, it's a great opportunity to highlight some of his work and I'm really happy to talk about it with you. Dr. Rafeh Naqash: Thanks, Tim. Definitely a huge loss for the scientific community. And I did see a while back that there was an international symposium organized, showcasing his work for him to talk about his journey last year where more than 200, 250 people from around the globe actually attended that. That speaks volumes to the kind of impact he's had as an individual and impact he's had on the scientific side of things as well. Dr. Timothy Showalter: Yes. And we just had the second annual Feng Symposium the day before ASCO GU this year with, again, a great turnout and some great science highlighted, as well as a real focus on mentorship and team science and collaboration. Dr. Rafeh Naqash: Thank you so much for telling us all about that. Now going to what you guys published in JCO Precision Oncology, which is this article on using a biomarker approach to stratify non-metastatic prostate cancer using this artificial intelligence based H&E score. Could you tell us the background for what started off this project? And I see there is a clinical trial data set that you guys have used, but there's probably some background to how this score or how this technology came into being. So, could you superficially give us an idea of how that started? Dr. Timothy Showalter: Sure. So, the multimodal AI score was first published in a peer reviewed journal back in 2022 and the test was originally developed through a collaboration with the Radiation Therapy Oncology Group or Energy Oncology Prostate Cancer Research Team. The original publication describes development and validation of a risk stratification tool designed to predict distant metastasis and prostate cancer specific mortality for men with localized prostate cancer. And the first validation was in men who were treated with definitive radiation therapy. There have been subsequent publications in that context and there's a set of algorithms that have been validated in localized prostate cancer and there's a test that's listed on NCCN guidelines based on that technology. The genesis for this paper was really looking at extending that risk stratification tool that was developed in localized prostate cancer to see if it could one, validate in a non-metastatic castrate refractory prostate cancer population for patients enrolled on the SPARTAN trial. And two, whether there was a potential role for the test output in terms of predicting benefit from apalutamide for patients with non-metastatic prostate cancer. For patients who are enrolled on the SPARTAN study, almost 40% of them had H&E stain biopsy slide material available and were eligible to be included in this study. Dr. Rafeh Naqash: Going a step back to how prostate cancer, perhaps on the diagnostic side using the pathology images is different as you guys have Gleason scoring, which to the best of my knowledge is not necessarily something that most other tumor types use. Maybe Ki-67 is somewhat of a comparison in some of the neuroendocrine cancers where high Ki-67 correlates with aggressive biology for prognosis. And similarly high Gleason scores, as we know for some of the trainees, correlates with poor prognosis. So, was the idea behind this based on trying to stratify or sub-stratify Gleason scoring further, where you may not necessarily know what to do with the intermediate high Gleason score individual tumor tissues? Dr. Timothy Showalter: Well, yeah. I mean, Gleason score is a really powerful risk stratification tool. As you know, our clinical risk groupings are really anchored to Gleason scores as an important driver for that. And while that's a powerful tool, I think, you know, some of the original recognition for applying computer vision AI into this context is that there are likely many other features located in the morphology that can be used to build a prognostic model. Going back to the genesis of the discovery project for the multimodal AI model, I think Felix Feng would have described it as doing with digital pathology and computer vision AI what can otherwise be done with gene expression testing. You know, he would have approached it from a genomic perspective. That's what the idea was. So, it's along the line of what you're saying, which is to think about assigning a stronger Gleason score. But I think really more broadly, the motivation was to come up with an advanced complementary risk stratification tool that can be used in conjunction with clinical risk factors to help make better therapy recommendations potentially. So that was the motivation behind it. Dr. Rafeh Naqash: Sure. And one of the, I think, other important teaching points we try to think about, trainees of course, who are listening to this podcast, is trying to differentiate between prognostic and predictive scores. So, highlighting the results that you guys show in relation to the MMAI score, the digital pathology score, and outcomes as far as survival as well as outcomes in general, could you try to help the listeners understand the difference between the prognostic aspect of this test and the predictive aspect of this test? Dr. Timothy Showalter: So let me recap for the listeners what we found in the study and how it kind of fits into the prognostic and the predictive insights. So, one, you know, as I mentioned before, this is ultimately a model that was developed and validated for localized prostate cancer for risk stratification. So, first, the team looked at whether that same tool developed in localized prostate cancer serves as a prognostic tool in non-metastatic castrate-refractory prostate cancer. So, we applied the tool as it was previously developed and identified that about 2/3 of patients on the SPARTAN trial that had specimens available for analysis qualified as high risk and 1/3 of patients as either intermediate or low risk, which we called in the paper ‘non-high risk'. And we're able to show that the multimodal AI score, which ranges from 0 to 1, and risk group, was associated with metastasis free survival time to second progression or PFS 2 and overall survival. And so that shows that it performs as a prognostic tool in this setting. And this paper was the first validation of this tool in non-metastatic castrate-refractory prostate cancer. So, what that means to trainees is basically it helps you understand how aggressive that cancer is or better stratify the risk of progression over time. So that's the prognostic performance. Dr. Rafeh Naqash: Thank you for trying to explain that. It's always useful to get an example and understand the difference between prognostic and predictive. Now again, going back to the technology, which obviously is way more complicated than the four letter word MMAI, I per se haven't necessarily done research in this space, but I've collaborated with some individuals who've done digital pathology assessments, and one of the projects we worked on was TIL estimation and immune checkpoint related adverse events using some correlation and something that one of my collaborators had sent to me when we were working on this project as part of this H&E slide digitalization, you need color deconvolution, you need segmentation cell profiling. Superficially, is that something that was done as part of development of this MMAI score as well? Dr. Timothy Showalter You need a ground truth, right? So, you need to train your model to predict whatever the outcome is. You know, if you're designing an AI algorithm for Ki-67 or something I think you mentioned before, you would need to have a set of Ki-67 scores and train your models to create those scores. In this case, the clinical annotation for how we develop the multimodal AI algorithm is the clinical endpoints. So going back to how this tool was developed, the computer vision AI model is interpreting a set of features on the scan and what it's trying to do is identify high risk features and make a map that would ultimately predict clinical outcomes. So, it's a little bit different than the many digital pathology algorithms where the AI is being trained to predict a particular morphological finding. In this case, the ground truth that the model is trained to predict is the clinical outcome. Dr. Rafeh Naqash: Sure. And from what you explained earlier, obviously, tumors that had a high MMAI score were the ones that were benefiting the most from the ADT plus the applausive. Is this specific for this androgen receptor inhibitor or is it interchangeable with other inhibitors that are currently approved? Dr. Timothy Showalter: That's a great question and we don't know yet. So, as you're alluding to, we did find that the MMAI risk score was predictive for benefit from apalutamide and so it met the statistical definition of having a significant interaction p value so we can call it a predictive performance. And so far, we've only looked in this population for apalutamide. I think you're raising a really interesting point, which is the next question is, is this generalizable to other androgen receptor inhibitors? There will be future research looking at that, but I think it's too early to say. Just for summary, I think I mentioned before, there are about 40% of patients enrolled on the SPARTAN study had specimens available for inclusion in this analysis. So, the SPARTAN study did show in the entire clinical trial set that patients with non-metastatic castrate-refractory prostate cancer benefited from apalutamide. The current study did show that there seems to be a larger magnitude of benefit for those patients who are multimodal AI high risk scores. And I think that's very interesting research and suggests that there's some interaction there. But I certainly would want to emphasize that we have not shown that patients with intermediate or low risk don't benefit from apalutamide. I think we can say that the original study showed that that trial showed a benefit and that we've got this interesting story with multimodal AI as well. Dr. Rafeh Naqash: Sure. And I think from a similar comparison, ctDNA where ctDNA shows prognostic aspects, I treat people with lung cancer especially, and if you're ctDNA positive at a 3 to 4-month period, likely chances of you having a shorter disease-free interval is higher. Same thing I think for colorectal cancers. And now there are studies that are using ctDNA as an integral biomarker to stratify patients positive/negative and then decide on escalation/de-escalation of treatment. So, using a similar approach, is there something that is being done in the context of the H&E based stratification to de-intensify or intensify treatments based on this approach? Dr. Timothy Showalter: You're hitting right on the point in the most promising direction. You know, as we pointed out in the manuscript, one of the most exciting areas as a next step for this is to use a tool like this for stratification for prospective trials. The multimodal AI test is not being used currently in clinical trials of non-metastatic castrate-refractory prostate cancer, which is a disease setting for this paper. There are other trials that are in development or currently accruing where multimodal AI stratification approach is being taken, where you see among the high-risk scores, at least in the postoperative setting for a clinical trial that's open right now, high risk score patients are being randomized to basically a treatment intensification question. And then the multimodal AI low risk patients are being randomized to a de-intensification experimental arm where less androgen deprivation therapy is being given. So, I think it's a really promising area to see, and I think what has been shown is that this tool has been validated really across the disease continuum. And so, I think there are opportunities to do that in multiple clinical scenarios. Dr. Rafeh Naqash: Then moving on to the technological advancements, very fascinating how we've kind of evolved over the last 10 years perhaps, from DNA based biomarkers to RNA expression and now H&E. And when you look at cost savings, if you were to think of H&E as a simpler, easier methodology, perhaps, with the limitations that centers need to digitalize their slides, probably will have more cost savings. But in your experience, as you've tried to navigate this H&E aspect of trying to either develop the model or validate the model, what are some of the logistics that you've experienced can be a challenge? As we evolve in this biomarker space, how can centers try to tackle those challenges early on in terms of digitalizing data, whether it's simple data or slides for that matter? Dr. Timothy Showalter: I think there's two main areas to cover. One, I think that the push towards digitalization is going to be, I think, really driven by increasing availability and access to augmentative technologies like this multimodal AI technology where it's really adding some sort of a clinical insight beyond what is going to be generated through routine human diagnostic pathology. I think that when you can get these sorts of algorithms for patient care and have them so readily accessible with a fast turnaround time, I think that's really going to drive the field forward. Right now, in the United States, the latest data I've seen is that less than 10% of pathology labs have gone digital. So, we're still at an early stage in that. I hope that this test and similar ones are part of that push to go more digital. The other, I think, more interesting challenge that's a technical challenge but isn't about necessarily how you collect the data, but it certainly creates data volume challenges, is how do you deal with image robustness and sort of translating these tools into routine real-world settings. And as you can imagine, there's a lot of variation for staining protocols, intensity scanner variations, all these things that can affect the reliability of your test. And at least for this research group that I'm a part of that has developed this multimodal AI tool can tell you that the development is sophisticated, but very data and energy intensive in terms of how to deal with making a tool that can be consistent across a whole range of image parameters. And so that presents its own challenges for dealing with a large amount of compute time and AI cycles to make robust algorithms like that. And practically speaking, I think moving into other diseases and making this widely available, the size of data required and the amount of cloud compute time will be a real challenge. Dr. Rafeh Naqash: Thank you for summarizing. I can say that definitely, you know, this is maybe a small step in prostate cancer biomarker research, but perhaps a big step in the overall landscape of biomarker research in general. So definitely very interesting. Now, moving on to the next part of the discussion is more about you as a researcher, as an individual, your career path, if you can summarize that for us. And more interestingly, this intersection between being part of industry as well as academia for perhaps some of the listeners, trainees who might be thinking about what path they want to choose. Dr. Timothy Showalter: Sure. So, as you may know, I'm a professor at the University of Virginia and I climbed the academic ladder and had a full research grant program and thought I'd be in academia forever. And my story is that along the way, I kind of by accident ended up founding a medical device company that was called Advaray and that was related to NCI SBIR funding. And I found myself as a company founder and ultimately in that process, I started to learn about the opportunity to make an impact by being an innovator within the industry space. And that was really the starting point for me. About four years ago, soon after Felix Feng co-founded Artera, he called me and told me that he needed me to join the company. For those who were lucky to know Felix well, at that very moment, it was inevitable that I was going to join Artera and be a part of this. He was just so persuasive. So, I will say, you know, from my experience of being sort of in between the academic and industry area, it's been a really great opportunity for me to enter a space where there's another way of making an impact within cancer care. I've gotten to work with top notch collaborators, work on great science, and be part of a team that's growing a company that can make technology like this available. Dr. Rafeh Naqash: Thank you so much, Tim, for sharing some of those thoughts and insights. We really appreciate you discussing this very interesting work with us and also appreciate you submitting this to JCO Precision Oncology and hopefully we'll see more of this as this space evolves and maybe perhaps bigger more better validation studies in the context of this test. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

How powerful is exercise in the fight against advanced prostate cancer? Dr. Geo speaks with world-renowned exercise oncology expert Dr. Rob Newton from Australia, whose groundbreaking research has shaped how clinicians approach fitness and cancer care. From bone metastasis to androgen deprivation therapy (ADT), Dr. Newton explains how the right exercise, at the right dose, can not only improve quality of life but potentially extend it.Together, they explore the science, practical guidelines, and inspiring stories behind using movement as medicine—even for men with metastatic, castration-resistant disease.Key TakeawaysExercise is medicine for men with prostate cancer—including advanced and metastatic cases.Resistance training helps preserve or build muscle during androgen deprivation therapy (ADT), reducing side effects like fatigue, bone loss, and metabolic issues.Even with bone metastases, exercise can be done safely with modified strength programs—no increase in fractures observed in studies.Muscle strength and fitness are strongly linked to lower cancer-related and all-cause mortality.Myokines released from working muscles have direct anti-cancer effects and support immune function.Focus on large muscle groups (legs, back, chest) using moderate to heavy weights—6 to 15 reps per set.Tailor workouts to the individual: more strength training for muscle loss, more cardio for heart/metabolic risk.Periodized, varied routines improve outcomes and help patients tolerate treatments like chemo better._________________________ Introducing The Dr. Geo Prostate Podcast Exclusive MembershipWe'll continue bringing you powerful weekly episodes to support your prostate health journey. But if you're ready to dive deeper, the Exclusive Membership gives you more: curated transcripts, detailed show notes, expert resources, and member-only perks—all designed to help you live better with age. Join HERE [https://drgeo.com/membership]_________________________ Thank you to our partnersThe ProLon 5-Day Fasting Mimicking Diet is a plant-based meal program designed to provide fasting benefits while allowing food intake. Developed by Dr. Valter Longo, it supports cellular renewal, fat loss, and metabolic health through low-calorie, pre-packaged meals that keep the body in a fasting state.Special Offer: As a listener, you can get the ProLon kit for just $148 using this [https://bit.ly/3TVehAx ].We'd also like to thank our partner AG1 by Athletic Greens. AG1 includes 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This blend supports your gut, immune system, energy, focus, and more—all in one daily scoop. https://bit.ly/3mA2tVV_________________________

The Ramblin Gambler, answers listeners questions in a Questions My Sons Ask segment (12:30), before revealing an additional secret ADT consideration casino use to determine how players are comped in a Core Koncepts segment (26:30). Then, TRG continues to share results from playing Beyond the Book, as taught by authors Bruce Dye and Dave Krite (40:38). Finally, in the Virtual VIP Lounge, TRG shares a free opportunity that he things every listeners should take advantage of (50:)0).

Jessica Zwaan returned to The Modern People Leader for a deep dive on how her PeopleOps as a Product philosophy came to life. We talked about the early days of the framework, writing her book, and the launch of MPL Build — a new collaboration between MPL and Jessica to bring the methodology to more teams.---- 

Shane Koller joined us on The Modern People Leader. We talked about adopting a product mindset in HR, how Ancestry's people team built their “product roadmap”, and why even great HR programs fall short when they're not connected.---- 

Eric Beyrich says, “this is the time of year we actually thrive” as he looks at a low-bid, high-yield strategy. He compares the ratio of value to growth in the market and says there's a “long way to go” to get back to equilibrium after tech's massive run. He expects the S&P 500 to have a bad year, but most stocks to have an up year. His picks include ADT, DOW, PFE, AMCR, and BERY.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Michele Bousquet joined us on The Modern People Leader. We talked about her career journey, leading with heart, and why HR shouldn't be so complicated.---- 

Michael Walsh, CEO of Cariloop, joined us on The Modern People Leader. We discussed the caregiving challenges facing employees today, how companies can better support working caregivers, and the data-backed insights from Cariloop's Top Needs Report.---- 

This week we wrap up Black History month, and Jim's guest is one of the most consequential black marketing leaders of all time. Jerri DeVard, the Founder and CEO of BECA, the Black Executive CMO Alliance. Jerri started her career in marketing the same year Jim joined Procter & Gamble; she also started in consumer goods, working 10 years at the Pillsbury company, now part of General Mills. Jerri went on to CMO roles at Verizon, Nokia, ADT and Office Depot. Jerri was a guest on the show in July 2020. Jim and Jerri chatted through a wide ranging talk about her career, our friendship over the years, and what she has learned about leadership. Well this week, Jim will focus on her life since then, including the founding of BECA, which has been astounding in its impact. It's an honest, heart-to-heart chat–which is the only way Jerri DeVard rolls. Listen to the previous episode featuring Jeri from 2020: https://tinyurl.com/3tcmrx9rLearn more about BECA: https://blackexec.com/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.